1287 related articles for article (PubMed ID: 31361123)
61. Application of model systems to study adaptive responses of Mycobacterium tuberculosis during infection and disease.
Gordhan BG; Peters J; Kana BD
Adv Appl Microbiol; 2019; 108():115-161. PubMed ID: 31495404
[TBL] [Abstract][Full Text] [Related]
62. Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.
Cavalier JF; Spilling CD; Durand T; Camoin L; Canaan S
Eur J Med Chem; 2021 Jan; 209():112908. PubMed ID: 33071055
[TBL] [Abstract][Full Text] [Related]
63. Cell Surface Biosynthesis and Remodeling Pathways in Mycobacteria Reveal New Drug Targets.
Shaku M; Ealand C; Kana BD
Front Cell Infect Microbiol; 2020; 10():603382. PubMed ID: 33282752
[No Abstract] [Full Text] [Related]
64. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality?
Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S
Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243
[TBL] [Abstract][Full Text] [Related]
65. Bottlenecks and opportunities in antibiotic discovery against Mycobacterium tuberculosis.
Craggs PD; de Carvalho LPS
Curr Opin Microbiol; 2022 Oct; 69():102191. PubMed ID: 35970040
[TBL] [Abstract][Full Text] [Related]
66. New perspectives on the treatment of mycobacterial infections using antibiotics.
He Y; Fan A; Han M; Zhang Y; Tong Y; Zheng G; Zhu S
Appl Microbiol Biotechnol; 2020 May; 104(10):4197-4209. PubMed ID: 32185432
[TBL] [Abstract][Full Text] [Related]
67. Tuberculosis drug targets.
Zhang Y; Amzel LM
Curr Drug Targets; 2002 Apr; 3(2):131-54. PubMed ID: 11958297
[TBL] [Abstract][Full Text] [Related]
68. Vitamins Based Novel Target Pathways/Molecules as Possible Emerging Drug Targets for the Management of Tuberculosis.
Sharma A; Jain K; Flora SJS
Med Chem; 2018; 14(3):212-224. PubMed ID: 29110620
[TBL] [Abstract][Full Text] [Related]
69. The Mycobacterium tuberculosis Uganda II family and resistance to first-line anti-tuberculosis drugs in Uganda.
Ezati N; Lukoye D; Wampande EM; Musisi K; Kasule GW; Cobelens FG; Kateete DP; Joloba ML
BMC Infect Dis; 2014 Dec; 14():703. PubMed ID: 25523472
[TBL] [Abstract][Full Text] [Related]
70. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
Ma S; Jaipalli S; Larkins-Ford J; Lohmiller J; Aldridge BB; Sherman DR; Chandrasekaran S
mBio; 2019 Nov; 10(6):. PubMed ID: 31719182
[TBL] [Abstract][Full Text] [Related]
71. Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis.
Reiche MA; Warner DF; Mizrahi V
Front Mol Biosci; 2017; 4():75. PubMed ID: 29184888
[No Abstract] [Full Text] [Related]
72. Resistance and tolerance of Mycobacterium tuberculosis to antimicrobial agents-How M. tuberculosis can escape antibiotics.
Li H; Yuan J; Duan S; Pang Y
WIREs Mech Dis; 2022 Nov; 14(6):e1573. PubMed ID: 35753313
[TBL] [Abstract][Full Text] [Related]
73. Autophagy Induction as a Host-Directed Therapeutic Strategy against
Adikesavalu H; Gopalaswamy R; Kumar A; Ranganathan UD; Shanmugam S
Medicina (Kaunas); 2021 May; 57(6):. PubMed ID: 34070995
[TBL] [Abstract][Full Text] [Related]
74.
Mashabela GT; de Wet TJ; Warner DF
Microbiol Spectr; 2019 Jul; 7(4):. PubMed ID: 31350832
[No Abstract] [Full Text] [Related]
75. Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs.
Mascarello A; Chiaradia-Delatorre LD; Mori M; Terenzi H; Botta B
Curr Pharm Des; 2016; 22(12):1561-9. PubMed ID: 26759082
[TBL] [Abstract][Full Text] [Related]
76. Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them.
Evangelopoulos D; da Fonseca JD; Waddell SJ
Int J Infect Dis; 2015 Mar; 32():76-80. PubMed ID: 25809760
[TBL] [Abstract][Full Text] [Related]
77. New treatment options for multidrug-resistant tuberculosis.
Field SK; Fisher D; Jarand JM; Cowie RL
Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
[TBL] [Abstract][Full Text] [Related]
78. Targeting Genome Integrity in
Miggiano R; Morrone C; Rossi F; Rizzi M
Molecules; 2020 Mar; 25(5):. PubMed ID: 32156001
[No Abstract] [Full Text] [Related]
79. New tuberculosis drug leads from naturally occurring compounds.
Quan D; Nagalingam G; Payne R; Triccas JA
Int J Infect Dis; 2017 Mar; 56():212-220. PubMed ID: 28062229
[TBL] [Abstract][Full Text] [Related]
80. ATP Synthase, an Emerging Target in TB Drug Discovery: Review of SAR and Clinical Pharmacology of Diarylquinoline Inhibitors.
Dhulap A; Banerjee P
Curr Drug Targets; 2021; 22(11):1207-1221. PubMed ID: 33480344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
